Two current projects, which are a cost-sharing effort between 12 members of RegenMed Development Organization and the Medical Technology Enterprise Consortium, aim to advance platform technologies that address regenerative medicine manufacturing challenges.
Humanoid Sensor Consortium
The consortium pools stakeholder talents, resources and ideas to address industry-wide challenges in developing new drugs and predicting responses of drugs, as well as personalized medicine applications and clinical trial design.
The Humanoid Sensor Consortium will utilize the Wake Forest Institute for Regenerative Medicine’s (WFIRM) “Body-on-a-Chip” system. This system allows scientists to engineer an advanced 3D model of the human body using a system of chips and microfluidic devices, creating a structure in which to place the humanoid tissue equivalents. These tissue equivalents function in a very similar manner as actual human organs. For example, the heart beats about 60 times each minute, the lung breathes the air from the surrounding environment, and the liver breaks down toxic compounds into harmless waste products.
One project is developing a universal bioink with tunable mechanical properties for additive manufacturing (3D bioprinting) of implantable regenerative medicine clinical products.
Universal Cell Media
Another project is developing a universal cell media that will be a GMP-grade-defined formulation that can help accelerate cell therapy and tissue engineering manufacturing product development.